SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-098049
Filing Date
2024-08-16
Accepted
2024-08-16 16:05:09
Documents
12
Period of Report
2024-08-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acst-20240812.htm   iXBRL 8-K 44316
2 EX-10.1 acst-ex10_1.htm EX-10.1 39359
  Complete submission text file 0000950170-24-098049.txt   205137

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT acst-20240812.xsd EX-101.SCH 24881
14 EXTRACTED XBRL INSTANCE DOCUMENT acst-20240812_htm.xml XML 4701
Mailing Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540
Business Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540 609-649-9272
Acasti Pharma Inc. (Filer) CIK: 0001444192 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A8 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-35776 | Film No.: 241216674
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)